Successfully reported this slideshow.
We use your LinkedIn profile and activity data to personalize ads and to show you more relevant ads. You can change your ad preferences anytime.

Chronic lymphocytic leukemia

3,564 views

Published on

Published in: Health & Medicine, Technology
  • Be the first to comment

Chronic lymphocytic leukemia

  1. 1. By Shimaa Abd Alla Ahmed
  2. 2. defenition  Progressive accumulation of matureappearing, functionally incompetent,longlived B lymphocytes in peripheral blood, bone marrow, lymph nodes,spleen, liver and sometimes other organs.
  3. 3. Diagnosis: NCI guidelines for CLL VARIABLE CBC CLL SLL ≥5; B-cell Marker (CD19, <5 B-Cell Marker CD20, (CD19, CD20, CD23) + CD5 CD23) + CD5 MBL <5 B-Cell Marker (CD19, CD20, CD23) + CD5 Lymphadenopath y+organomegaly No aneamia No thrombocytobenia BM >30% lymphocyte STAGING RIA,BINET Ann Arpor
  4. 4. Incidence  Commonest leukaemia in Western adults (25–30% of all leukaemias).  2.5/100,000 per year.  Age  Predominantly disease of elderly Median age at diagnosis 65 years. (in over 70s,>20/100,000).  m:f ratio ~2:1.  Marked geographic difference e.g. In China & Japan = 1/10 of Western world.
  5. 5. Aetiology  Unknown. No causal relationship with radiation, chemicals or viruses.  Small proportion are familial. Genetic factors suggested by low incidence in Japanese even after emigration.  Lymphocyte accumulation appears to result from defects in intracellular apoptotic pathways: 90% of CLL cases have high levels of BCL-2 which blocks apoptosis.
  6. 6. Clinical features and presentation  asymptomatic; lymphocytosis (>5.0 ¥ 109/L) on routine FBC.  Lymphadenopathy: painless, often symmetrical,splenomegaly (66%), hepatomegaly  BM failure due to infiltration causing  anaemia,  neutropenia and  thrombocytopenia.  Recurrent infection due to acquired hypogammaglobulinaemia: esp.Herpes zoster.
  7. 7. Lymphadenopathy
  8. 8. Lymphadenopathy
  9. 9. • Patients with advanced disease:B-symptoms: FUO. Night sweats. Wt loss. general malaise.  Autoimmune phenomena occur;  DAT +ve in 10–20% cases, warm antibodyAIHA in <50% of these cases.  Autoimmune thrombocytopenia in 1–2%.
  10. 10. Diagnosis  FBC:  lymphocytosis >5.0 109/L  Neutropenia  anaemia,  thrombocytopenia and  absent in early stageCLL;  autoimmune haemolysis occur at any stage. thrombocytopenia may
  11. 11. Morphology: Peripheral Blood •Absolute lymphocytosis > 5 X 109 /L. Mature looking lymphocytes; characteristic artefactual damage to cells in film preparation produces numerous ‘smear cells’ (Note:absence of smear cells should prompt review of diagnosis); •Morphological subtypes: Atypical or mixed CLL/PLL: > 10% & < 54% prolymphocytes. •Morphology is usually not enough to differentiate from reactive lymphocytosis. spherocytes,polychromasia Increase retics if AIHA;
  12. 12. Comparison of CLL and PLL B-CLL CLL-PLL CLL slg CD19 CD20 CD5 PLL + ++ ++ ++ ++ ++ ++ -/+ Courtesy of Randy Gascoyne, MD. 1. Bennett JM, et al. J Clin Pathol. 1989;42:567-584.
  13. 13. Immunophenotyping  crucial to differentiation from other lymphocytoses  First line panel: CD20; CD5; CD19; CD23; FMC7; SmIg, CD22 or CD79b.  CLL characteristically CD20 and FMC7 – ve;  CD5,CD19 and CD23 +ve;  SmIg, CD22, CD79b weak;  k or l light chain restricted.  CD 38.Zab 70
  14. 14. Immunophenotype scoring system Scoring system for B-CLL Points Membrane marker Smlg 1 0 Weak Moderate/strong CD5 Positive Negative CD23 Positive Negative FMC7 Negative Positive CD79b (SN8) Negative Positive 1. Matutes E, et al. Leukemia. 1994;8:1640-1645. 2. Moreau EJ, et al. Am J Clin Pathol. 1997;108:378-382.
  15. 15.  Immunoglobulins:  immuneparesis (hypogammaglobulinaemia) common;  monoclonal paraprotein (usually IgM) <5%.  Bone marrow: >30% ‘mature’ lymphocytes.  Trephine biopsy: provides prognostic information: infiltration may be  nodular (favourable); interstitial; mixed; diffuse (unfavourable).  Lymph node biopsy: rarely required; appearances of lymphocytic lymphoma.
  16. 16. Bone marrow
  17. 17. Prognosis: histologic bone Nodular Interstitial Diffuse marrow patterns (low risk) (low risk) (high risk)  The different bone marrow patterns probably variations in amount of lymphoid accumulation the natural course of the disease Courtesy of Randy Gascoyne, MD. 1. Montserrat E, et al. Cancer. 1984;54:447-451. reflect during
  18. 18. Cytogenetics  Conventional chromosome banding can no longer be recommended in the diagnostic work up of CLL ( detects abnormalities in 40-50 % of CLL patients only.
  19. 19. Cytogenetics  prognostic value; abnormalities in >80% using FISH:  13q–(55%),  11q– (18%),  12q+ (16%),  17p– (7%),  6q– (7%);  11q–, 17q– veryunfavourable; sole 13q–favourable,or 6q– ,normal karotyping neutral out come ,Clonal evolution occurs over time.  11q– and 17q– associated with advanced disease.
  20. 20. Molecular biology:  IgV genes mutational status:  Relates to stage of differentiation of malignant B-cells  Accordingly there are 2 variants of CLL : * Pre-germinal variant : - Naive B-lymphocytes with no IgV gene mutation (CD38+ve) - Unfavorable clinical outcome . * Post-germinal Variant : - Originates from memory B-lymphocytes, exhibiting IgV mutation (CD38 – ve) - Favorable clinical outcome • bcl-2: > 85% of B-cell cases express high levels of bcl-2 which is a potent inhibitor of apoptosis (programmed cell death). p53: • The p53 tumour suppressor gene is mutated in 8 % B-cell cases.
  21. 21. Other tests:  U&E; LFTs;  LDH;  Uric acide  b2-microglobulin;  imaging .  Ct chest and abdomine  Pet scan(With richter transformation)
  22. 22. Poor prognostic factors  male sex.  Advanced clinical stage.  Initial lymphocytosis > 50 ¥ 109/L.  >5% prolymphocytes in blood film.  Diffuse pattern of infiltrate on trephine.  Blood lymphocyte doubling time <12 months.  Cytogenetic abnormalities 11q– or 17q–.  serum b2-microglobulin.  serum LDH.  serum thymidine kinase.  soluble CD23.  Unmutated IgVH genes.  Poor response to therapy.
  23. 23. Staging: Rai and Binet staging systems for CLL Clinical staging systems for CLL Stage Value Rai Binet Median survival Lymphocytosis (>15,000/mm3) 0 - 150 months (12.5 years) Lymphocytosis plus nodal involvement I A Lymphocytosis plus organomegaly II B Anemia (RBCs) III Hgb <11 g/dL <3 node groups >3 node groups Hgb <10 g/dL C Lymphocytosis plus IV thrombocytopenia PLT <100,000/mm3 1. Rai KR, et al. Blood. 1975;46:219-234. (platelets) 2. Binet JL, et al. Cancer. 1981;48:198-206. 3. Binet JL, et al. Cancer. 1977;40:855-864. PLT <100,000/mm3 101-108 months (8.5-9 years) 60-71 months (5-6 years) 19-24 months (1.5-2 years)
  24. 24. Response criteria to NCI guidelines for CLL Variable Response criteria CR NCI Physical exam Symptoms Lymphocytes (x 109/L) Neutrophils (x 109/L) Platelets (x 109/L) Hemoglobin (g/dL) Bone marrow lymphs (%) Normal None ≤4 ≥1.5 >100 >11 (untransfused) <30, no nodules PR Physical exam (nodes and/or liver, spleen) Plus ≥1 of: Neutrophils (x 109/L) Platelets (x 109/L) Hemoglobin (g/dL) Duration of CR or PR 1. Cheson BD, et al. Blood. 1996;87:4990-4997. ≥50% decrease ≥1.5 >100 >11 or 50% improvement ≥2 months
  25. 25. PD: •Physical ex. (LN , liver , spleen): > 50% increase or new •Circulating lymphocytes : > 50 % increase.. •Others: Richter’s syndrome SD: •All 0ther than the above.
  26. 26. Cll ttt acording to NCCN 2013 Chemotherapy reserved for patients with symptomatic or progressive disease: 1. anaemia (Hb <10g/dL) 2. Thrombocytopenia (<100 ¥109/L), 3. Constitutional Symptoms Due To CLL (>10% Weight Loss In 6 Months, Fatigue, Fever, Night Sweats), 4. Progressive Lymphocytosis: Doubling Time <6 Months, 5. SymptomaticLymphadenopathy>10cm splenomegay>6cm BCM, Autoimmune Disease Refractory To Steroids, 6. Repeated Infections Hypogammaglobulinaemia.
  27. 27. Frail patient with significant comorbidity  Chlorampucil ±rituximab  Rituximab  Pulse steriod
  28. 28. Cll patients indicated to ttt Fish T(11,14) Del 13 Del11 Del17 1-cll without del 17p,11q 2-cll with del17p 3-cll with del 11q
  29. 29. Cll without del 17p,11q >70 years ,significant comorbidiyy  Chlorampucil ±rituximab  bendamastine  Cyclophosphamide,predni      slone±R Rituximab Alemtuzumab Fludarabine±R Cladripine Lenalidomide <70 years , no significant comorbidiyy     FCR FR PCR(Pentostatin) bendamastine±R
  30. 30. Cll without del 17p,11q Relapse, no response >70 years ,significant comorbidiyy  Reduced dose FCR,PCR  Bendamastine±R  Chlorampucil ±rituximab  Alemtuzumab±R  Lenalidomide±R  HDMP+R <70 years , no significant comorbidiyy           FCR PCR(Pentostatin) bendamastine±R F+Alemtuzemab Alemtuzemab±R R-CHOP OFAR R-HYPER CVAD Lenalidomide±R Then allogenic SCT
  31. 31. Cll with del 17p short term relapse,no response First line therapy  FCR  FR  Alemtuzumab±R  HDMP+R  Then allogenic SCT         Alemtuzumab±R RCHOP CFAR OFAR HDMP+R R±hyper CVAD Lenalidomide±R Then allogenic SCT
  32. 32. Cll Without Del 11q >70 years ,significant comorbidiyy  Chlorampucil ±rituximab  Bendamastine  Cyclophosphamide,predni      slone±R Rituximab Alemtuzumab Fludarabine±R Cladripine Lenalidomide <70 years , no significant comorbidiyy  FCR  PCR(Pentostatin)  bendamastine±R  Then allogenic SCT with PR,opserve With CR
  33. 33. Cll without del 11q Relapse, no response >70 years ,significant comorbidiyy  Reduced dose FCR,PCR  Bendamastine±R  Chlorampucil ±rituximab  Alemtuzumab±R  Lenalidomide±R  HDMP+R <70 years , no significant comorbidiyy          FCR PCR(Pentostatin) bendamastine±R F+Alemtuzemab Alemtuzemab±R R-CHOP R-HYPER CVAD Lenalidomide±R Then allogenic SCT
  34. 34. Treatment of CLL CHLORAMBUCIL: •Still the primary therapy of choice for older patients. •CR rates: 8-13%. •Addition of steroids: No advantage except in autoimmune cytopenias. •Dose: 0.4 mg/kg day 1 (repeat every 2 weeks) or 0.1 mg/kg day 1-14 (repeat every 4 weeks) •For how long?: Till max. response (may take months). •Maintenance treatment: No advatage in CLL. •Progress after 12 months of max. response: You may repeat the same dose.
  35. 35. Treatment of CLL FLUDARABINE (Purine analog): •Salvage treatment in older patients. •Primary treatment in young patients who will receive stem cell transplantaion. •It is the most active single agent in CLL. •CR rates: 25% (up to 20 months duration) even if strict NCI WG criteria are used. •Most CR cases occur in the first 3 months of • treatment. Dose: 25 mg / m2 D 1-5 repeated every 4 weeks for 3 - 6 cycles. Side effects:•Lymphocytopenia + opportunistic infections. •AIHA (contraindicated if AIHA is already present). •Tumour lysis syndrome in the first cycle if counts are very high due to rapid response. •Transfusion-associated GVHD (irradiate blood components).
  36. 36. Treatment of CLL CLADARABINE (2CdA, Leustatin) •Purine analog •Same effect in CLL as Fludarabine •Dose: 0.1 mg / kg D 1-7 repeated every 4 weeks for 3-6 cycles. •Side effects:- Almost the same like Fludarabine.
  37. 37. Treatment of CLL (MONOCLONAL AB) 2- Campath-1H  Anti CD 52 antibody (CD 52 present on most B &T cells )  Response rates 50 %  Toxicities : rigors,chills, fever,immunosuppression & lymphocytopenia .  CMV re-activation is a problem 3- Rituximab ( anti-CD20)  In CLL CD 20 is moderately expressed on the cells ( possible reason for low response rates )  With high counts (TLC > 50,000) patient may develop “cytokine release syndrome” (fever, rigor, skin rash , nausea, vomiting, hypotension, & dyspnea )
  38. 38. Stem Cell Transplantation • The only treatment modality that resulted in PCR-negative CRs in a substantial number of patients. • Minitransplants can be applied to a higher age range group.  Cll with del 17p after first crif patient eligible with doner  Cll with del11q after first pr if patient eligible with doner  Cll with relapse after receiving high dose chemotherapy
  39. 39. Complications of cll  Recurrent infection(neutropenia,immunoparesis)  Ivig  Antimicrobial agent  Anti infective prophylaxis  Herpes  Sulfa(neumocystic)  CMV(alemtuzemab)  Autoimmune disease  ITP,AIHA,PRCA  steriod,rituximab,cyclosporine,splenectomy  Fludarabine is contraindicated with AIHA
  40. 40. Complicatins of cll  Vaccination  Influanza  Pneumococal vaccin  Avoid live vaccine  Blood products(irradiated blood)  Tumour lysis syndrome  Tumour flair syndrome(lenalidomide)  Ttt steriod  Thrompoprophylaxis(asprine81 mg/day) with lenalidomide

×